General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0GJRTI
ADC Name
EGC-PABQ-DuoDM gluc ADC
Synonyms
EGC-PABQ-DuoDM gluc ADC
   Click to Show/Hide
Organization
University of Texas Health Science Center at Houston.; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences.
Drug Status
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
H231
 Antibody Info 
Antigen Name
Epiregulin (EREG)
 Antigen Info 
Payload Name
Duocarmycin DM
 Payload Info 
Linker Name
DBCO-PEG3-EGC-PABQ
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
ADC-specific functional property(2027 Update)
Binding Affinity
Click To Hide/Show 1 ADC-specific functional property Data
Dissocation Constant (Kd) Binding Target Description Reference
≈2 nM
DLD1 cells
Prior to evaluating therapeutic efficacy, we measured binding of all three EREG ADCs in parallel in DLD1 cells. All ADCs demonstrated comparable binding affinities (Kd≈2.0 nmol/L).
[1]
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 7 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.01&#1770.004
nM
CVCL_0399
Colon adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
0.02&#1770.009
nM
CVCL_0291
Colon carcinoma
Half Maximal inhibitory Concentration (lC50) 
0.14&#1770.16
nM
CVCL_0248
Colon adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
0.31&#1770.05
nM
CVCL_1724
Colon adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
> 10000
nM
CVCL_0248
Colon adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
> 10000
nM
CVCL_0547
Colon adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
> 10000
nM
CVCL_0504
Colon carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 7 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.01&#1770.004 nM High EREG expression (EREG +++)
Method Description
Colorectal cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).

   Click to Show/Hide
In Vitro Model Colon adenocarcinoma LoVo cells CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.02&#1770.009 nM High EREG expression (EREG +++)
Method Description
Colorectal cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).

   Click to Show/Hide
In Vitro Model Colon carcinoma HCT116 cells CVCL_0291
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.14&#1770.16 nM High EREG expression (EREG +++)
Method Description
Colorectal cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).

   Click to Show/Hide
In Vitro Model Colon adenocarcinoma DLD-1 cells CVCL_0248
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.31&#1770.05 nM Moderate EREG expression (EREG++)
Method Description
Colorectal cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).

   Click to Show/Hide
In Vitro Model Colon adenocarcinoma SW48 cells CVCL_1724
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 10000 nM Negative EREG expression (EREG-)
Method Description
Colorectal cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).

   Click to Show/Hide
In Vitro Model Colon adenocarcinoma DLD-1 cells (EREG KO) CVCL_0248
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 10000 nM Low EREG expression (EREG+)
Method Description
Colorectal cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).

   Click to Show/Hide
In Vitro Model Colon adenocarcinoma SW620 cells CVCL_0547
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 10000 nM Low EREG expression (EREG+)
Method Description
Colorectal cancer cells were plated at ~1,000 cells/well in 96-half-well plates. Serial dilutions of unconjugated H231, cmAb, H231 ADCs, or cADC were added and incubated at 37°C for 4 or 5 days. Cell viability was measured using CellTiter-Glo 2.0 (Promega, cat. #G9242) according to the manufacturer's protocol. Luminescence was measured using a Tecan Infinite M1000 plate reader (RRID: SCR_025732).

   Click to Show/Hide
In Vitro Model Colon carcinoma RKO cells CVCL_0504
References
Ref 1 Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer